Multi-omics Mendelian Randomization Analysis for IBS Drug Target Discovery

A tabular dataset presents results from a druggable genome-wide Mendelian randomization analysis integrating GWAS and eQTL data to identify causal gene targets for irritable bowel syndrome. The analysis evaluated 5,642 protein-coding genes using summary statistics from a GWAS with 53,400 cases and 433,201 controls. The dataset was authored by Huiwen Ke and published on figshare in May 2026.

Use Cases

• Prioritizing candidate drug targets for IBS based on causal associations identified through Mendelian randomization.
• Evaluating potential on-target adverse effects using phenome-wide association study (PheWAS) results.
• Identifying existing therapeutic compounds for predicted targets via molecular docking predictions.
• Validating genetic findings for drug development through colocalization analysis.

Strengths

• Analysis integrates summary statistics from a large-scale IBS GWAS with 53,400 cases and 433,201 controls.
• Systematic evaluation covers 5,642 potential druggable protein-coding genes.
• Results are validated with colocalization analysis and include PheWAS for adverse effect assessment.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is 93.2 KB, indicating a limited scope likely containing summary results rather than raw data.

Provenance

Source

figshare

Collection Method

Druggable genome-wide Mendelian randomization analysis integrating GWAS and eQTL summary statistics.

Freshness

Last updated 2026-05-18 22:02:55; freshness should be verified.